Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2018 Jul 30;7(4):869–896. doi: 10.1016/S0272-2712(18)30721-2

Antiviral Chemotherapyand Prophylaxis of Viral Respiratory Disease

Steven J Sperber *, Frederick G Hayden †,**
PMCID: PMC7131954  PMID: 2446820

Abstract

Several antiviral agents are currently available for the treatment and prophylaxis of viral respiratory disease. These include oral amantadine for influenza A and aerosolized ribavirin for respiratory syncytial virus infections. Additional agents, such as rimantadine and intranasal interferons, and newer approaches, including thе use of combination chemotherapy, offer promise for the improved management of viral respiratory tract infections.

References

  • 1.Abraham G., Colonno R.J. Many rhinovirus serotypes share the same cellular receptor. J Virol. 1984;51:340. doi: 10.1128/jvi.51.2.340-345.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Advisory Committee on Immunization Practices Prevention and control of influenza. MMWR. 1986;35:317. [Google Scholar]
  • 3.Ahmad A.L.M., Tyrrell D.A.J. Synergism between anti-rhinovirus antivirals: Various human interferons and a number of synthetic compounds. Antiviral Res. 1986;6:241. doi: 10.1016/0166-3542(86)90005-7. [DOI] [PubMed] [Google Scholar]
  • 4.Al-Nakib W., Higgins P.G., Willman J. Prevention and treatment of experimental influenza A virus infection in volunteers with a new antiviral ICI 130, 685. J Antimicrob Chemother. 1986;18:119. doi: 10.1093/jac/18.1.119. [DOI] [PubMed] [Google Scholar]
  • American Academy of Pediatrics Policy statement—ribavirin therapy of respiratory syncytial virus. AAP News. 1986 December. [Google Scholar]
  • 5.Aoki F.Y., Sitar D.S. Amantadine kinetics in healthy elderly men: Implications for influenza prevention. Clin Pharmacol Ther. 1985;37:137. doi: 10.1038/clpt.1985.25. [DOI] [PubMed] [Google Scholar]
  • 6.Aoki F.Y., Stiver H.G., Sitar D.S. Prophylactic amantadine dose and plasma concentration—effect relationships in healthy adults. Clin Pharmacol Ther. 1985;37:128. doi: 10.1038/clpt.1985.24. [DOI] [PubMed] [Google Scholar]
  • 7.Armstrong J.A., Skicki-Mullen M.B., Breinig M.K. Interferon susceptibility of herpes simplex virus strains isolated from patients enrolled in clinical trials. Antimicrob Agents Chemother. 1983;24:137. doi: 10.1128/aac.24.1.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Atkinson W.L., Arden N.H., Patriarca P.A. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med. 1986;146:1751. [PubMed] [Google Scholar]
  • 9.Barker W.H. Excess pneumonia and influenza associated hospitalization during influenza A epidemics in the U.S., 1970-1978. In: Kendal A.P., Patriarca P.A., editors. UCLA Symposia on Molecular and Cellular Biology, New Series, Volume 36: Options for the Control of Influenza. Alan R Liss; New York: 1986. pp. 75–87. [Google Scholar]
  • 10.Barry W., Cockburn F., Cornall R. Ribavirin aerosol for acute bronchiolitis. Arch Dis Child. 1986;61:593. doi: 10.1136/adc.61.6.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Betts RF, Erb S, Roth F, et al: A field trial of intranasal interferon (abstract SE 4.7/1-5). Proc Thirteenth Int Congr Chemotherapy, Vienna, August 28-September 2, 1983, p 60/13
  • 12.Bleidner W.E., Harmon J.B., Hewes W.E. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965;150:484. [PubMed] [Google Scholar]
  • 13.Browne M.J. Comparative inhibition of influenza and parainfluenza virus replication by ribavirin in MDCK cells. Antimicrob Agents Chemother. 1981;19:712. doi: 10.1128/aac.19.5.712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Browne M.J., Moss M.Y., Boyd M.R. Comparative activity of amantadine and ribavirin against influenza virus in vitro: Possible clinical relevance. Antimicrob Agents Chemother. 1983;23:503. doi: 10.1128/aac.23.3.503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Buchdahl R.M., Taylor P., Warner J.O. Nebulized ribavirin for adenovirus pneumonia. Lancet. 1985;2:1070. doi: 10.1016/s0140-6736(85)90941-9. [DOI] [PubMed] [Google Scholar]
  • 16.Bukrinskaya A.G., Vorkunova N.K., Kornilayeva G.V. Influenza virus uncoating in infected cells and effect of rimantadine. J Gen Virol. 1982;60:49. doi: 10.1099/0022-1317-60-1-49. [DOI] [PubMed] [Google Scholar]
  • 17.Bukrinskaya S.G., Vorkunova N.K., Pushkarskaya N.L. Uncoating of rimantadine-resistant variant of influenza virus in the presence of rimantadine. J Gen Virol. 1982;60:61. doi: 10.1099/0022-1317-60-1-61. [DOI] [PubMed] [Google Scholar]
  • 18.Burlington D.B., Meiklejohn G., Mostow S.R. Anti-influenza A virus activity of amantadine hydrochloride and rimantadine hydrochloride in ferret tracheal ciliated epithelium. Antimicrob Agents Chemother. 1982;21:794. doi: 10.1128/aac.21.5.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Came P.E., Schafer T.W., Silver G.H. Sensitivity of rhinoviruses to human leukocyte and fibroblast interferons. J Infect Dis. 1976;133:A136. doi: 10.1093/infdis/133.supplement_2.a136. [DOI] [PubMed] [Google Scholar]
  • 20.Carr A.B., Einstein R., Nai L.Y.C. Vitamin С and the common cold using identical twins as controls. Med J Aust. 1981;2:411. doi: 10.5694/j.1326-5377.1981.tb101032.x. [DOI] [PubMed] [Google Scholar]
  • 21.Casey D.E. Amantadine intoxication reversed by physostigmine. N Engl J Med. 1978;298:516. doi: 10.1056/nejm197803022980919. [DOI] [PubMed] [Google Scholar]
  • 22.Catlin D.H., Smith R.A., Samuels A.I. 14C-Ribavirin: Distribution and pharmacokinetic studies in rats, baboons and man. In: Smith R.A., Kirkpatric W., editors. Ribavirin—A Broad Spectrum Antiviral Agent. Academic Press; New York: 1980. pp. 83–98. [Google Scholar]
  • 23.Chalmers T.C. Effects of ascorbic acid on the common cold: An evaluation of the evidence. Am J Med. 1975;58:532. doi: 10.1016/0002-9343(75)90127-8. [DOI] [PubMed] [Google Scholar]
  • 24.Clover R.D., Crawford S.A., Abell T.D. Effectiveness of rimantadine prophylaxis of children within families. Am J Dis Child. 1986;140:706. doi: 10.1001/archpedi.1986.02140210104036. [DOI] [PubMed] [Google Scholar]
  • 25.Cochran K.W., Maassab H.F., Tsunoda A. Studies on the antiviral activity of amantadine hydrochloride. Ann NY Acad Sci. 1965;130:432. doi: 10.1111/j.1749-6632.1965.tb12579.x. [DOI] [PubMed] [Google Scholar]
  • 26.Cohen A., Togo Y., Khakoo R. Comparative clinical and laboratory evaluation of the prophylactic capacity of ribavirin, amantadine hydrochloride, and placebo in induced human influenza type A. J Infect Dis. 1976;133:Al14. doi: 10.1093/infdis/133.supplement_2.a114. [DOI] [PubMed] [Google Scholar]
  • 27.Colonno R.J., Callahan P.L., Long W.J. Isolation of a monoclonal antibody that blocks attachment to the major group of human rhinoviruses. J Virol. 1986;57:7. doi: 10.1128/jvi.57.1.7-12.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Connor J.D. Comparative pharmacology of nucleoside analogs with antiviral activity. In: Mills J., Corey L., editors. Antiviral Chemotherapy: New Directions for Clinical Application and Research. Elsevier Science Publishing Co; New York: 1986. pp. 138–154. [Google Scholar]
  • 29.Couch R.B. The common cold: Control? J Infect Dis. 1984;150:167. doi: 10.1093/infdis/150.2.167. [DOI] [PubMed] [Google Scholar]
  • 30.Couch R.B., Jackson G.G. Antiviral agents in influenza—summary of influenza workshop VIII. J Infect Dis. 1976;34:516. doi: 10.1093/infdis/134.5.516. [DOI] [PubMed] [Google Scholar]
  • 31.Couch R.B., Six H.R. The antiviral spectrum and mechanism of action of amantadine and rimantadine. In: Mills J., Corey L., editors. Antiviral Chemotherapy: New Directions for Clinical Application and Research. Elsevier Science Publishing Co; New York: 1986. pp. 50–57. [Google Scholar]
  • 32.Davis W.L., Grunert R.R., Haff R.F. Antiviral activity of 1-adamantanamine (amantadine) Science. 1964;144:826. doi: 10.1126/science.144.3620.862. [DOI] [PubMed] [Google Scholar]
  • 33.DeLong D.C. Microbiology. American Society for Microbiology; Washington, DC: 1984. Effect of enviroxime on rhinovirus infections in humans; pp. 431–434. [Google Scholar]
  • 34.DeLong D.C., Reed S.E. Inhibition of rhinovirus replication in organ culture by a potential antiviral drug. J Infect Dis. 1980;141:87. doi: 10.1093/infdis/141.1.87. [DOI] [PubMed] [Google Scholar]
  • 35.Dick E.C., Hossain S.U., Mink K.A. Interruption of transmission of rhinovirus colds among human volunteers using virucidal paper handkerchiefs. J Infect Dis. 1986;153:352. doi: 10.1093/infdis/153.2.352. [DOI] [PubMed] [Google Scholar]
  • 36.Dixon R.E. Economic costs of respiratory tract infections in the United States. Am J Med. 1985;78:45. doi: 10.1016/0002-9343(85)90363-8. Suppl 6B. [DOI] [PubMed] [Google Scholar]
  • 37.Dolin R, Betts RF, Treanor J, et al: Intranasally administered interferon as prophylaxis (abstract SE 4.7/1-7). Proc Thirteenth Int Congr Chemotherapy, Vienna, August 28-September 3, 1983, p 60/20
  • 38.Dolin R., Betts R.F., Treanor J.J. Las Vegas. American Society for Microbiology; Washington DC: 1983. Rimantadine prophylaxis of influenza in the elderly (abstract 691). Program and Abstracts of the Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy; p. 210. October 24-26, 1983. [Google Scholar]
  • 39.Dolin R., Reichman R.C., Madore H.P. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med. 1982;307:580. doi: 10.1056/NEJM198209023071002. [DOI] [PubMed] [Google Scholar]
  • 40.Douglas RM: Personal communication
  • 41.Douglas R.M., Albrecht J.K., Miles H.B. Intranasal interferon-α2 prophylaxis of natural respiratory virus infection. J Infect Dis. 1985;151:731. doi: 10.1093/infdis/151.4.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Douglas R.M., Moore B.W., Miles H.B. Prophylactic efficacy of intranasal alpha2-interferon against rhinovirus infections in the family setting. N Engl J Med. 1986;314:65. doi: 10.1056/NEJM198601093140201. [DOI] [PubMed] [Google Scholar]
  • 43.Eby G.A., Davis D.R., Halcomb W.W. Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother. 1984;25:20. doi: 10.1128/aac.25.1.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Edelson P.J., Welliver R.C. The immunology of infection with respiratory syncytial virus (RSV) Pediatr Virol. 1987;2(1):1. [Google Scholar]
  • 45.Elwood P.C., Hughes S.J., St Leger A.S. A randomized controlled trial of the therapeutic effect of vitamin С in the common cold. Practitioner. 1977;218:133. [PubMed] [Google Scholar]
  • 46.Farr BM: Personal communication
  • 47.Farr B.M., Gwaltney J.M., Jr., Adams K.F. Intranasal interferon-α2 for prevention of natural rhinovirus colds. Antimicrob Agents Chemother. 1984;26:31. doi: 10.1128/aac.26.1.31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Fishaut M. Amantadine for severe influenza A pneumonia in infancy. J Dis Child. 1980;134:321. doi: 10.1001/archpedi.1980.02130150075022. [DOI] [PubMed] [Google Scholar]
  • 49.Fox M.P., Otto M.J., McKinlay M.A. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob Agents Chemother. 1986;30:110. doi: 10.1128/aac.30.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Galbraith A.W., Oxford J.S., Schild G.C. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment. Lancet. 1969;2:1026. doi: 10.1016/s0140-6736(69)90639-4. [DOI] [PubMed] [Google Scholar]
  • 51.Galegov G.A., Pushkarskaya N.L., Obrosova-Serova N.P. Combined action of ribavirin and rimantadine in experimental myxovirus infection. Expérimenta. 1977;33:905. doi: 10.1007/BF01951273. [DOI] [PubMed] [Google Scholar]
  • 52.Gallagher J.G., Khoobyarian N. Adenovirus susceptibility to interferon: Sensitivity of types 2,7, and 12 to human interferon. Proc Soc Exp Biol Med. 1969;130:137. doi: 10.3181/00379727-130-33506. [DOI] [PubMed] [Google Scholar]
  • 53.Gallagher J.G., Khoobyarian N. Sensitivity of adenovirus types 1,3,4,5,8,11, and 18 to human interferon. Proc Soc Exp Biol Med. 1971;136:920. doi: 10.3181/00379727-136-35395. [DOI] [PubMed] [Google Scholar]
  • 54.Gangemi J.D., Nachtigal M., Barnhart D. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J Infect Dis. 1987;155:510. doi: 10.1093/infdis/155.3.510. [DOI] [PubMed] [Google Scholar]
  • 55.Geist F.C., Bateman J.A., Hayden F.G. In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother. 1987;31:622. doi: 10.1128/aac.31.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Gelfand E.W., McCurdy D., Rao C.P. Ribavirin treatment of viral pneumonitis in severe combined immunodeficiency disease. Lancet. 1983;2:732. doi: 10.1016/s0140-6736(83)92265-1. [DOI] [PubMed] [Google Scholar]
  • 57.Gilbert B.E., Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother. 1986;30:201. doi: 10.1128/aac.30.2.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Gilbert B.E., Wilson S.Z., Knight V. Ribavirin small-particle aerosol treatment of infections caused by influenza virus strains A/Victoria/7/83 (H1N1) and B/Texas/1/84. Antimicrob Agents Chemother. 1985;27:309. doi: 10.1128/aac.27.3.309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Greenberg S.B., Harmon M.W., Johnson P.E. Antiviral activity of intranasally applied human leukocyte interferon. Antimicrob Agents-Chemother. 1978;14:596. doi: 10.1128/aac.14.4.596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Gwaltney J.M., Jr., Hendley J.O. Transmission of experimental rhinovirus infection by contaminated surfaces. Am J Epidemiol. 1982;116:828. doi: 10.1093/oxfordjournals.aje.a113473. [DOI] [PubMed] [Google Scholar]
  • 61.Gwaltney J.M., Jr., Moskalski P.B., Hendley J.O. Interruption of experimental rhinovirus transmission. J Infect Dis. 1980;142:811. doi: 10.1093/infdis/142.6.811. [DOI] [PubMed] [Google Scholar]
  • 62.Hall C.B., McBride J.T., Gala C.L. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA. 1985;254:3047. [PubMed] [Google Scholar]
  • 63.Hall C.B., McBride J.T., Nevil L.E. Comment. Pediatr Infect Dis. 1986;5:708. [Google Scholar]
  • 64.Hall C.B., McBride J.T., Walsh E.E. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. N Engl J Med. 1983;308:1443. doi: 10.1056/NEJM198306163082403. [DOI] [PubMed] [Google Scholar]
  • 65.Hall C.B., Powell K.R., MacDonald N.E. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315:77. doi: 10.1056/NEJM198607103150201. [DOI] [PubMed] [Google Scholar]
  • 66.Hall C.B., Walsh E.E., Hruska J.F. Ribavirin treatment of experimental respiratory syncytial viral infection. JAMA. 1983;249:2666. [PubMed] [Google Scholar]
  • Hall C.B., Dolin R., Gala C.L. Children with influenza A infection: Treatment with rimantadine. Pediatrics. 1987;80:275. [PubMed] [Google Scholar]
  • 67.Harmon M.W., Greenberg S.B., Couch R.B. Effect of human nasal secretions on the antiviral activity of human fibroblast and leukocyte interferon. Proc Soc Exp Biol Med. 1976;152:598. doi: 10.3181/00379727-152-39448. [DOI] [PubMed] [Google Scholar]
  • 68.Hay A.J., Zambon M.C., Wolstenholme A.J. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother. 1986;18:19. doi: 10.1093/jac/18.supplement_b.19. Suppl B. [DOI] [PubMed] [Google Scholar]
  • 69.Hayden F.G. Combinations of antiviral agents for treatment of influenza virus infections.c. J Antimicrob Chemother. 1986;18:177. doi: 10.1093/jac/18.supplement_b.177. Suppl B. [DOI] [PubMed] [Google Scholar]
  • 70.Hayden FG: Intranasal interferons for control of respiratory viral infections. In Revel M (ed): Clinical Aspects of Interferons. Norwell, Massachusetts, Martinus Nijhoff Publishing, in press
  • 71.Hayden F.G. Use of interferons for prevention and treatment of respiratory viral infections. In: Mills J., Corey L., editors. Antiviral Chemotherapy: New Directions for Clinical Application and Research. Elsevier Science Publishing Co; New York: 1986. pp. 28–39. [Google Scholar]
  • 72.Hayden F.G., Albrecht J.K., Kaiser D.L. Prevention of natural colds by contact prophylaxis with intranasal alpha2-interferon. N Engl J Med. 1986;314:71. doi: 10.1056/NEJM198601093140202. [DOI] [PubMed] [Google Scholar]
  • 73.Hayden F.G., Cote K.M., Douglas R.G., Jr. Plaque inhibition assay for drug susceptibility testing of influenza viruses. Antimicrob Agents Chemother. 1980;17:865. doi: 10.1128/aac.17.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Hayden F.G., Gwaltney J.M., Jr. Intranasal interferon-α2 for prevention of rhinovirus infection and illness. J Infect Dis. 1983;148:543. doi: 10.1093/infdis/148.3.543. [DOI] [PubMed] [Google Scholar]
  • 75.Hayden F.G., Gwaltney J.M., Jr. Intranasal interferon-α2 treatment of experimental rhinovirus colds. J Infect Dis. 1984;150:174. doi: 10.1093/infdis/150.2.174. [DOI] [PubMed] [Google Scholar]
  • 76.Hayden F.G., Gwaltney J.M., Jr. Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother. 1982;21:892. doi: 10.1128/aac.21.6.892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Hayden FG, Gwaltney JM Jr, Colonno RJ: Effect of intranasal rhinovirus receptor monoclonal antibody on the course of experimentally induced rhinovirus type 39 infection in man. Program of the American Society for Virology 1986 Annual Meeting, Santa Barbara, California, June 22-26, 1986, p 54
  • 78.Hayden F.G., Gwaltney J.M., Jr., Johns M.E. Prophylactic efficacy and tolerance of low-dose intranasal interferon-alpha2 in natural respiratory viral infections. Antiviral Res. 1985;5:111. doi: 10.1016/0166-3542(85)90037-3. [DOI] [PubMed] [Google Scholar]
  • 79.Hayden F.G., Gwaltney J.M., Jr., Van de Castle R.L. Comparative toxicity of amantadine hydrochloride and rimantadine hydrochloride in healthy adults. Antimicrob Agents Chemother. 1981;19:226. doi: 10.1128/aac.19.2.226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Hayden F.G., Hall W.J., Douglas R.G., Jr. Therapeutic effects of aerosolized amantadine in naturally acquired infection due to influenza A virus. J Infect Dis. 1980;141:535. doi: 10.1093/infdis/141.5.535. [DOI] [PubMed] [Google Scholar]
  • 81.Hayden F.G., Hoffman H.E., Spyker D.A. Differences in side effects of amantadine hydrochloride and rimantadine hydrochloride relate to differences in pharmacokinetics. Antimicrob Agents Chemother. 1983;23:458. doi: 10.1128/aac.23.3.458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Hayden F.G., Innés D.J., Jr., Mills S.E. Long-term tolerance of intranasal recombinant interferon betaser in man. J Interferon Res. 1986;6(1):31. [Google Scholar]
  • 83.Hayden F.G., Laskin O.L., Douglas R.G., Jr. Susceptibility testing of viruses and pharma-codynamics of antiviral agents. In: Lorian V., editor. Antivirals in Laboratory Medicine. Edition 2. Williams & Wilkins; Baltimore: 1986. pp. 359–380. [Google Scholar]
  • 84.Hayden F.G., Mills S.E., Johns M.E. Human tolerance and histopathologic effects of long-term administration of intranasal interferon-α2. J Infect Dis. 1983;148:914. doi: 10.1093/infdis/148.5.914. [DOI] [PubMed] [Google Scholar]
  • 85.Hayden F.G., Minocha A., Spyker D.A. Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob Agents Chemother. 1985;28:216. doi: 10.1128/aac.28.2.216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Hayden F.G., Monto A.S. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. Antimicrob Agents Chemother. 1986;29:339. doi: 10.1128/aac.29.2.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Hayden F.G., Schlepushkin A.N., Pushkarskaya N.L. Combined interferon-α2, rimantadine hydrochloride, and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother. 1984;25:53. doi: 10.1128/aac.25.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Hayden F.G., Winther B., Donowitz G.R. Human nasal mucosal responses to topically applied recombinant leukocyte A interferon. J Infect Dis. 1987;156:64. doi: 10.1093/infdis/156.1.64. [DOI] [PubMed] [Google Scholar]
  • 89.Hayden F.G., Zylidnikov D.M., Iljenko V.I. Comparative therapeutic effect of aerosolized and oral rimantadine HCl in experimental human influenza A virus infection. Antiviral Res. 1982;2:147. doi: 10.1016/0166-3542(82)90016-x. [DOI] [PubMed] [Google Scholar]
  • 90.Heider H., Adamczyk B., Presber H.W. Occurrence of amantadine-and rimantadine-resistant influenza A virus strains during the 1980 epidemic. Acta Virol. 1981;25:395. [PubMed] [Google Scholar]
  • 91.Hendley J.O., Hayden G.F. The effect of placebo and virucidal paper handkerchiefs on iral contamination of the hand and transmission of experimental rhinoviral infection. J Infect Dis. 1985;152:403. doi: 10.1093/infdis/152.2.403. [DOI] [PubMed] [Google Scholar]
  • 92.Hendley J.O., Mika L.A., Gwaltney J.M., Jr. Evaluation of virucidal compounds for inacti vation of rhinovirus on hands. Antimicrob Agents Chemother. 1978;14:690. doi: 10.1128/aac.14.5.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93.Hicks R.A., Olson L.C., Jackson M.A. Precipitation of ribavirin causing obstruction of ventilation tube. Ped Infect Dis. 1986;5:707. doi: 10.1097/00006454-198611000-00025. [DOI] [PubMed] [Google Scholar]
  • 94.Higgins P.G., Al-Nakib W., Tyrrell D.A.J. Interferon-αser as prophylaxis against experimental rhinovirus infection in volunteers. J Interferon Res. 1986;6:153. doi: 10.1089/jir.1986.6.153. [DOI] [PubMed] [Google Scholar]
  • 95.Higgins P.G., Phillpotts R.J., Scott G.M. Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers. Antimicrob Agents Chemother. 1983;24:713. doi: 10.1128/aac.24.5.713. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.Hillyard I.W. The preclinical toxicology and safety of ribavirin. In: Smith R.A., Kirkpatric W., editors. Ribavirin—A Broad Spectrum Antiviral Agent. Academic Press; New York: 1980. pp. 59–71. [Google Scholar]
  • 97.Hoffmann C.E. Structure, activity and mode of action of amantadine HC1 and related compounds. Antibiotics Chemother. 1980;27:233. doi: 10.1159/000385395. [DOI] [PubMed] [Google Scholar]
  • 98.Horadam V.W., Sharp J.G., Smilack J.D. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med. 1981;94:454. doi: 10.7326/0003-4819-94-4-454. [DOI] [PubMed] [Google Scholar]
  • 99.Hruska J.F., Bernstein J.M., Douglas R.G., Jr. Effects of ribavirin on respiratory syncytial virus in vitro. Antimicrob Agents Chemother. 1980;17:770. doi: 10.1128/aac.17.5.770. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 100.Huffman J.H., Sidwell R.W., Khare G.P. In vitro effect of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob Agents Chemother. 1973;3:235. doi: 10.1128/aac.3.2.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101.Ing T.S., Daugirdas J.T., Soung L.S. Toxic effects of amantadine in patients with renal failure. Can Med Assoc J. 1979;120:695. [PMC free article] [PubMed] [Google Scholar]
  • 102.Ishitsuka H., Ninomiya Y.T., Ohsawa C. Direct and specific inactivation of rhinovirus by chalcone Ro 09-0401. Antimicrob Agents Chemother. 1982;22:617. doi: 10.1128/aac.22.4.617. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Ishitsuka H., Ninomiya Y., Ohsawa C. New antirhinovirus agents, Ro 09-0410 and Ro 09-0415. In: Periti P., Grassi G.G., editors. Vol. 2. American Society for Microbiology; Washington DC: 1982. pp. 1083–1085. (Current Chemotherapy and Immunotherapy. Proceedings of the 12th International Congress of Chemotherapy, Florence, Italy 1981.). [Google Scholar]
  • 104.Ishitsuka H., Ohsawa C., Ohiwa T. Antipicornavirus flavone Ro 09-0179. Antimicrob Agents Chemother. 1982;22:611. doi: 10.1128/aac.22.4.611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105.Joklik W.K. Interferons. In: Fields B.N., Knipe D.M., Chanock R.M., editors. Field’s Virology. Raven Press; New York: 1985. pp. 281–307. [Google Scholar]
  • 106.Karlowski T.R., Chalmers T.C., Frenkel L.D. Ascorbic acid for the common cold: A prophylactic and therapeutic trial. JAMA. 1975;231:1038. [PubMed] [Google Scholar]
  • 107.Kato N., Eggers H.J. Inhibition of uncoating of fowl plague virus by 1-adamantanamine hydrochloride. Virology. 1969;37:632. doi: 10.1016/0042-6822(69)90281-5. [DOI] [PubMed] [Google Scholar]
  • 108.Knight V., Bloom K., Wilson S.Z. Amantadine aerosol in humans. Antimicrob Agents Chemother. 1979;16:572. doi: 10.1128/aac.16.5.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 109.Knight V., Gilbert B.E. Chemotherapy of respiratory viruses. In: Stollerman H., Harrington W.J., Lamont J.T., editors. Vol. 31. Year Book Medical Publishers; Chicago: 1986. pp. 95–118. (Advances in Internal Medicine). [Google Scholar]
  • 110.Knight V., McClung H.W., Wilson S.Z. Ribavirin small-particle aerosol treatment of influenza. Lancet. 1981;2:945. doi: 10.1016/s0140-6736(81)91152-1. [DOI] [PubMed] [Google Scholar]
  • 111.Korant B.D., Kauer J.C., Butterworth B.E. Zinc ions inhibit replication of rhinoviruses. Nature. 1974;248:588. doi: 10.1038/248588a0. [DOI] [PubMed] [Google Scholar]
  • 112.Larsson A., Stenberg K., Oberg B. Reversible inhibition of cellular metabolism by ribavirin. Antimicrob Agents Chemother. 1978;13:154. doi: 10.1128/aac.13.2.154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 113.Little J.W., Hall W.J., Douglas R.G., Jr. Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. Am Rev Resp Dis. 1978;118:295. doi: 10.1164/arrd.1978.118.2.295. [DOI] [PubMed] [Google Scholar]
  • 114.Little J.W., Hall W.J., Douglas R.G., Jr. Amantadine effect on peripheral airways abnormalities in influenza. Ann Intern Med. 1976;85:177. doi: 10.7326/0003-4819-85-2-177. [DOI] [PubMed] [Google Scholar]
  • 115.Magnussen C.R., Douglas R.G., Jr., Betts R.F. Double-blind evaluation of oral ribavirin (virazole) in experimental influenza A virus infection in volunteers. Antimicrob Agents Chemother. 1977;12:498. doi: 10.1128/aac.12.4.498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116.Mardiney M.R., Jr., Bredt A.B. The immunosuppressive effect of amantadine upon the response of lymphocytes to specific antigens in vitro. Transplantation. 1971;12:183. doi: 10.1097/00007890-197109000-00006. [DOI] [PubMed] [Google Scholar]
  • 117.McClung H.W., Knight V., Gilbert B.E. Ribavirin aerosol treatment of influenza В virus infection. JAMA. 1983;249:2671. [PubMed] [Google Scholar]
  • 118.McIntosh K. Chemotherapy of respiratory syncytial virus infections. In: Mills J., Corey L., editors. Antiviral Chemotherapy: New Directions for Clinical Application and Research. Elsevier Science Publishing; New York: 1986. pp. 83–88. [Google Scholar]
  • 119.McIntosh K., Kurachek S.C., Cairns L.M. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol. Am J Dis Child. 1984;138:305. doi: 10.1001/archpedi.1984.02140410083024. [DOI] [PubMed] [Google Scholar]
  • 120.McKinlay M.A., Frank J.A. Win 51711—a novel drug for the treatment of enterovirus infections. In: Mills J., Corey L., editors. Antiviral Chemotherapy: New Directions for Clinical Application and Research. Elsevier Science Publishing; New York: 1986. pp. 90–96. [Google Scholar]
  • 121.Miller F.D., Monto A.S., Delong D.C. Controlled trial of enviroxime against natural rhinovirus infections in a community. Antimicrob Agents Chemother. 1985;27:102. doi: 10.1128/aac.27.1.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122.Millet V.M., Dreisbach M., Bryson Y.J. Double-blind controlled study of central nervous system side effects of amantadine, rimantadine, and chlorpheniramine. Antimicrob Agents Chemother. 1982;21:1. doi: 10.1128/aac.21.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 123.Monto A.S., Gunn R.A., Bandyk M.G. Prevention of Russian influenza by amantadine. JAMA. 1979;241:1003. [PubMed] [Google Scholar]
  • 124.Monto A.S., Shope T.C., Schwartz S.A. Intranasal interferon-2αb for seasonal prophylaxis of respiratory infection. J Infect Dis. 1986;154:128. doi: 10.1093/infdis/154.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 125.Müller W.E.G., Maidhof A., Taschner H. Virazole (l-β-D-ribofuranosyl-l,2,4-triazole-3-carboxamide: A cytostatic agent. Biochem Pharmacol. 1977;26:1071. doi: 10.1016/0006-2952(77)90246-5. [DOI] [PubMed] [Google Scholar]
  • 126.Murphy B.R., Richman D.D., Chalhub E.G. Failure of attenuated temperature sensitive influenza A (H3N2) virus to induce heterologous interference in humans to parainfluenza type 1 virus. Infect Immun. 1975;12:62. doi: 10.1128/iai.12.1.62-68.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 127.Ninomiya Y., Ohsawa C., Aoyama M. Antiviral agent Ro 09-0410 binds to rhinovirus specifically and stabilizes the virus conformation. Virology. 1984;134:269. doi: 10.1016/0042-6822(84)90296-4. [DOI] [PubMed] [Google Scholar]
  • 128.Oxford J.S., Galbraith A. Antiviral activity of amantadine: A review of laboratory and clinical data. Pharmacol Ther. 1980;11:181. doi: 10.1016/0163-7258(80)90072-8. [DOI] [PubMed] [Google Scholar]
  • 129.O’Donoghue J.M., Ray C.G., Terry D.W., Jr. Prevention of nosocomial influenza infection with amantadine. Am J Epidemiol. 1973;97:276. doi: 10.1093/oxfordjournals.aje.a121509. [DOI] [PubMed] [Google Scholar]
  • 130.Patriarca P.A., Kater N.A., Kendal A.P. Safety of prolonged administration of rimantadine hydrochloride in the prophylaxis of influenza A virus infections in nursing homes. Antimicrob Agents Chemother. 1984;26:101. doi: 10.1128/aac.26.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 131.Payler D.K., Purdham P.A. Influenza A prophylaxis with amantadine in a boarding school. Lancet. 1984;1:502. doi: 10.1016/s0140-6736(84)92861-7. [DOI] [PubMed] [Google Scholar]
  • 132.Pettersson R.F., Hellstrom P.E., Penttinen K. Evaluation of amantadine in the prophylaxis of influenza A (H1N1) virus infection: A controlled field trial among young adults and high-risk patients. J Infect Dis. 1980;142:377. doi: 10.1093/infdis/142.3.377. [DOI] [PubMed] [Google Scholar]
  • 133.Phillpotts R.J., Davies H.W., Tyrrell D.A.J. Pharmacokinetics of intranasally applied medication during a cold. Antiviral Res. 1984;4:71. doi: 10.1016/0166-3542(84)90027-5. [DOI] [PubMed] [Google Scholar]
  • 134.Phillpotts R.J., Higgins P.G., Willman J.S. Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers. J Antimicrob Chemother. 1984;14:403. doi: 10.1093/jac/14.4.403. [DOI] [PubMed] [Google Scholar]
  • 135.Phillpotts R.J., Higgins P.G., Willman J.S. Intranasal lymphoblastoid interferon (“Wellferon”) prophylaxis against rhinovirus and influenza virus in volunteers. J Interferon Res. 1984;4:535. doi: 10.1089/jir.1984.4.535. [DOI] [PubMed] [Google Scholar]
  • 136.Phillpotts R.J., Jones R.W., DeLong D.C. The activity of enviroxime against rhinovirus infection in man. Lancet. 1981;1:1342. doi: 10.1016/s0140-6736(81)92520-4. [DOI] [PubMed] [Google Scholar]
  • 137.Phillpotts R.J., Wallace J., Tyrrell D.A.J. Therapeutic activity of enviroxime against rhinovirus infection in volunteers. Antimicrob Agents Chemother. 1983;23:671. doi: 10.1128/aac.23.5.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 138.Pitt H.A., Costrini M. Vitamin В prophylaxis in marine recruits. JAMA. 1979;241:908. [PubMed] [Google Scholar]
  • 139.Potter C.W., Phair J.P., Vodinelich L. Antiviral, immunosuppressive and antitumour effects of ribavirin. Nature. 1976;259:496. doi: 10.1038/259496a0. [DOI] [PubMed] [Google Scholar]
  • 140.Powers C.N., Pfavy D.L., Knight V. Selective inhibition of functional lymphocyte sub-populations by ribavirin. Antimicrob Agents Chemother. 1982;22:108. doi: 10.1128/aac.22.1.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 141.Richman D.D., Hostetler K.Y., Yazaki P.J. Fate of influenza A virion proteins after entry into subcellular fractions of LLC cells and the effect of amantadine. Virology. 1986;151:200. doi: 10.1016/0042-6822(86)90042-5. [DOI] [PubMed] [Google Scholar]
  • 142.Richman D.D., Murphy B.R., Baron S. Three stains of influenza A virus (H3N2): Interferon sensitivity in vitro and interferon production in volunteers. J Clin Microbiol. 1976;3:223. doi: 10.1128/jcm.3.3.223-226.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 143.Richman D.D., Yazaki P., Hostetler K.Y. The intracellular distribution of antiviral activity of amantadine. Virology. 1981;112:81. doi: 10.1016/0042-6822(81)90614-0. [DOI] [PubMed] [Google Scholar]
  • 144.Rodriguez W.J., Kim H.W., Brandt C.D. Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. Pediatr Infect Dis J. 1987;6:159. doi: 10.1097/00006454-198702000-00004. [DOI] [PubMed] [Google Scholar]
  • 145.Samo T.C., Greenberg S.B., Couch R.B. Efficacy and tolerance of intranasally applied recombinant leukocyte A interferon in normal volunteers. J Infect Dis. 1983;148:535. doi: 10.1093/infdis/148.3.535. [DOI] [PubMed] [Google Scholar]
  • 146.Scheffler P., Haghchenas D., Wigand R. The effect of purine and pyrimidine analogues and virazole on adenovirus replication. Acta Virol. 1975;19:106. [PubMed] [Google Scholar]
  • 147.Schulman J.L. Effect of 1-amantanamine hydrochloride (amantadine HC1) and methyl-1-adamantamethylamine hydrochloride (rimantadine HC1) on transmission of influenza virus infection in mice (33222) Proc Soc Exper Biol Med. 1968;128:1173. [Google Scholar]
  • 148.Schwab R.S., England A.C., Poskanzer D.C. Amantadine in the treatment of Parkinson’s disease. JAMA. 1969;208:1168. [PubMed] [Google Scholar]
  • 149.Scott G.M., Phillpotts R.J., Wallace J. Prevention of rhinovirus colds by human interferon alpha-2 from Escherichia coli. Lancet. 1982;2:186. doi: 10.1016/s0140-6736(82)91031-5. [DOI] [PubMed] [Google Scholar]
  • 150.Sidwell R.W., Huffman J.H., Khare G.P. Broad-spectrum antiviral activity of Virazole: l-β-D-ribofuranosyl-l,2,4-triazole-3-carboxamide. Science. 1972;177:705. doi: 10.1126/science.177.4050.705. [DOI] [PubMed] [Google Scholar]
  • 151.Sioufi A., Pommier F. Gas chromatographic determination of amantadine hydrochloride (Symmetrel) in human plasma and urine. J Chromatography. 1980;183:33. doi: 10.1016/s0378-4347(00)81395-x. [DOI] [PubMed] [Google Scholar]
  • 152.Smith C.B., Charette R.P., Fox J.P. Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection. J Infect Dis. 1980;141:548. doi: 10.1093/infdis/141.5.548. [DOI] [PubMed] [Google Scholar]
  • 153.Smith C.B., Purcell R.H., Chanock R.M. Effect of amantadine hydrochloride on parainfluenza type 1 virus infections in adult volunteers. Am Rev Resp Dis. 1967;95:689. doi: 10.1164/arrd.1967.95.4.689. [DOI] [PubMed] [Google Scholar]
  • 154.Smith T.J., Kremer M.J., Luo M. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science. 1986;233:1286. doi: 10.1126/science.3018924. [DOI] [PubMed] [Google Scholar]
  • 155.Spiegel R.J., Spicehandler J.R., Jacobs S.L. Low incidence of serum neutralizing factors in patients receiving recombinant alpha-2b interferon (Intron A) Am J Med. 1986;80:223. doi: 10.1016/0002-9343(86)90013-6. [DOI] [PubMed] [Google Scholar]
  • Staeheli P., Haller O., Boll W. Mx protein: Constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell. 1986;44:47. doi: 10.1016/0092-8674(86)90493-9. [DOI] [PubMed] [Google Scholar]
  • 156.Sun C-S, Wilson S.Z., Wyde P.R. Limited efficacy of aerosolized recombinant alpha interferon against virulent influenza A/HK infection in mice. Proc Soc Exp Biol Med. 1986;181:298. doi: 10.3181/00379727-181-42257. [DOI] [PubMed] [Google Scholar]
  • 157.Swallow D.L., Kampfner G.L. The laboratory selection of antiviral agents. Br Med Bull. 1985;41:322. doi: 10.1093/oxfordjournals.bmb.a072071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 158.Taber L.H., Knight V., Gilbert B.E. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983;72:613. [PubMed] [Google Scholar]
  • Thompson J., Fleet W., Lawrence E. A comparison of acetaminophen and rimantadine in the treatment of influenza A infection in children. J Med Viro. 1987;21:249. doi: 10.1002/jmv.1890210308. [DOI] [PubMed] [Google Scholar]
  • 159.Togo Y., McCracken E.A. Chemoprophylaxis and therapy of respiratory viral infections: Double-blind clinical assessment of ribavirin (Virazole) in the prevention of induced infection with type В influenza virus. J Infect Dis. 1976;133:A109. doi: 10.1093/infdis/133.supplement_2.a109. [DOI] [PubMed] [Google Scholar]
  • 160.Tsunoda A., Maassab H.F., Cochran K.W. Antiviral activity of a-methyl-l-adamantane-methylamine hydrochloride. Antimicrob Agents Chemother-1965. Ann Arbor, Am Soc Microbiol. 1966:553. doi: 10.1128/AAC.5.6.553. [DOI] [PubMed] [Google Scholar]
  • 161.Turner R.B., Felton A., Kosak K. Prevention of experimental coronavirus colds with intranasal -2b interferon. J Infect Dis. 1986;154:443. doi: 10.1093/infdis/154.3.443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 162.Tyrrell D.A.J., Craig J.W., Meade T.W. A trial of ascorbic acid in the treatment of the common cold. Br J Prev Soc Med. 1977;31:189. doi: 10.1136/jech.31.3.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163.Van Dyke R., Hintz M., Connor J.D. Program and Abstracts of the Twenty-second Interscience Conference on Antimicrobial Agents and Chemotherapy, Miami Beach, Florida, October 4-6, 1981. American Society for Microbiology; Washington DC: 1982. Pharmacology of ribavirin aerosol therapy in children (abstract 424) p. 141. [Google Scholar]
  • 164.Van Voris L.P., Bartram J., Hoffman H.E. Program and Abstracts of the Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, Nevada, October 24-26, 1983. American Society for Microbiology; Washington DC: 1983. Comparative pharmacokinetics of rimantadine HC1 and amantadine HC1 (abstract 684) p. 209. [Google Scholar]
  • 165.Van Voris L.P., Betts R.F., Hayden F.G. Successful treatment of naturally occurring influenza A/USSR/77 H1N1. JAMA. 1981;245:1128. doi: 10.1001/jama.245.11.1128. [DOI] [PubMed] [Google Scholar]
  • 166.Walker J.S., Stephen E.L., Spertzel R.O. Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice. J Infect Dis. 1976;133:A140. doi: 10.1093/infdis/133.supplement_2.a140. [DOI] [PubMed] [Google Scholar]
  • 167.Webster R.G., Kawaoka Y., Bean W.J. Chemotherapy and vaccination: A possible strategy for the control of highly virulent influenza virus. J Virol. 1985;55:173. doi: 10.1128/jvi.55.1.173-176.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168.WHO Viral respiratory diseases. WHO Technical Report Series No. 642. 1980:7–49. [PubMed] [Google Scholar]
  • 169.Wilfert C.M. Summary of discussion following the respiratory syncytial virus symposium. In: Mills J., Corey L., editors. Antiviral Chemotherapy: New Directions for Clinical Application and Research. Elsevier Science Publishing; New York: 1986. p. 89. [Google Scholar]
  • 170.Wilson S.Z., Gilbert B.E., Quarles J.M. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob Agents Chemother. 1984;26:200. doi: 10.1128/aac.26.2.200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171.Wilson S.Z., Knight V., Wyde P.R. Amantadine and ribavirin aerosol treatment of influenza A and В infection in mice. Antimicrob Agents Chemother. 1980;17:642. doi: 10.1128/aac.17.4.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 172.Wray S.K., Gilbert B.E., Knight V. Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro. Antiviral Res. 1985;4:39. doi: 10.1016/0166-3542(85)90013-0. [DOI] [PubMed] [Google Scholar]
  • 173.Wray S.K., Gilbert B.E., Noall M.W. Mode of action of ribavirin: Effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Antiviral Res. 1985;5:29. doi: 10.1016/0166-3542(85)90012-9. [DOI] [PubMed] [Google Scholar]
  • 174.Wray S.K., Smith R.H.A., Gilbert B.E. Effects of selenazofurin and ribavirin and their 5’-triphosphates on replicative functions of influenza A and В viruses. Antimicrob Agents Chemother. 1986;29:67. doi: 10.1128/aac.29.1.67. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175.Wright P.F., Khaw K.T., Oxman M.N. Evaluation of the safety of amantadine HC1 and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis. 1976;134:144. doi: 10.1093/infdis/134.2.144. [DOI] [PubMed] [Google Scholar]
  • 176.Wyde P.R., Wilson S.Z., Gilbert B.E. Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol. Antimicrob Agents Chemother. 1986;30:942. doi: 10.1128/aac.30.6.942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 177.Younkin S.W., Betts R.F., Roth F.K. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother. 1983;23:577. doi: 10.1128/aac.23.4.577. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178.Zlydnikov D.M., Kubar O.I., Kovaleva T.P. Study of rimantadine in the USSR: A review of the literature. Rev Infect Dis. 1981;3:408. doi: 10.1093/clinids/3.3.408. [DOI] [PubMed] [Google Scholar]

Articles from Clinics in Laboratory Medicine are provided here courtesy of Elsevier

RESOURCES